Santhera Eyes CHF 250 Million Revenue Target as German Price Cut Looms Over 2027

Santhera targets CHF 80-90M 2026 revenue and no further capital raises after H1 sales doubled, but flags a German price cut in early 2027.

Santhera Pharmaceuticals has sketched out a multi-year roadmap that would carry the Swiss specialty pharma group from its first commercial chapter into a self-sustaining business — and, crucially, one that management believes can be financed without tapping shareholders again.

That conviction rests on the company's cash position. As of June 30, 2026, Santhera held liquid funds of CHF 41.8 million, a buffer the company expects to keep broadly steady through year-end. On that basis, management concluded that no additional financing will be required, removing — at least for now — the threat of further capital increases. For smaller biotech and pharma names, persistent funding needs are often the single biggest valuation overhang, so the ability to press ahead with operations and commercialization without a fresh raise takes meaningful pressure off the stock.

First-Half Results Underpin the Ambition

The mid-term plan is anchored in the operating performance of the first six months of 2026. Total revenue doubled to CHF 48.3 million, with product sales contributing CHF 17.2 million. The operating loss narrowed to CHF 6.6 million, a sharp improvement from CHF 35.4 million in the prior-year period. That shrinking deficit does more than flatter the income statement — it eases the strain on the balance sheet and supports the goal of funding future growth largely from internal resources.

Commercial execution is advancing in parallel. AGAMREE, Santhera's lead therapy, is now available in four of Europe's five largest markets, following pricing and reimbursement agreements secured in Spain and Italy. Management reaffirmed its full-year 2026 guidance of CHF 80 million to CHF 90 million in total revenue, a range the market treats as a key credibility test for the longer-term projections. Santhera is counting on its widening footprint within national health systems to keep lifting demand for the treatment.

A German Headwind Takes Shape for Early 2027

Not everything on the horizon is favorable. Santhera expects cash to remain largely stable through the end of 2026 relative to the September 30 level, but has flagged a renewed outflow in the first half of 2027. Two factors drive that: planned investment in inventory build-up and a mandatory price reduction in Germany of roughly 8.5 percent starting in the first quarter of 2027.

The looming German discount illustrates how demanding the long-term commercialization of specialty pharmaceuticals in Europe remains. For Santhera, the priority will be ramping sales in newly opened markets quickly enough to offset the margin erosion. Higher distribution costs and market-preparation spending will continue to weigh on the balance sheet, keeping profitability under close scrutiny even as rising drug revenue absorbs a larger share of operating expenses.

Market Verdict So Far

Investors have given the story a warm reception this year. The shares closed Thursday at EUR 16.22, up 19 percent since the start of 2026. Attention now turns to whether Santhera can hit the interim milestones on the path toward its CHF 250 million revenue target for 2030 — and do so without diluting the shareholders who have backed the turnaround this far.